II
Stoppers, syringes & drug-contact components
Every injectable passes through elastomer stoppers and glass barrels from two or three qualified suppliers — West's near-monopoly is the textbook choke.
Every injectable drug — from insulin to monoclonal antibodies to the GLP-1 blockbusters now reshaping pharma — touches the same three things before it reaches a patient: a glass barrel or vial, an elastomer (rubber) closure, and increasingly an injection device that ties them together. None of these are the molecule. They are the drug-contact components that sit between a biologic and the human body, and they are supplied by a remarkably short list of qualified names. This is a manufacturing chokepoint, not a discovery story.
Who owns it
The elastomer closure layer is the textbook choke. West Pharmaceutical Services is the anchor: $3.074B FY2025 net sales (+6.3%), with high-value-product (HVP) components — coated stoppers and plungers like NovaPure and FluroTec — now 48% of sales and growing ~20% reported. West's moat is regulatory: a stopper is spec'd into a drug's FDA filing, so switching suppliers triggers a multi-year (reportedly 18–30 month) qualification and re-approval cycle. The other qualified elastomer names are Datwyler (CHF 1.10B 2025 revenue, Healthcare Solutions division) and Aptar Pharma, whose injectables division grew 18% in Q3 and 24% in Q4 2025 on GLP-1 elastomer demand. On the glass/barrel side, Stevanato Group (€1.186B FY2025, +7%) and Germany's Gerresheimer dominate prefillable syringes and cartridges; SHL Medical and Ypsomed own the autoinjector that wraps it all together.
What breaks it
The constraint is qualified capacity, not raw materials. GLP-1 demand has consumed the available pool of high-value syringes, cartridges, and coated stoppers faster than suppliers can validate new lines. Stevanato reports GLP-1/incretin therapies are now ~21–22% of revenue and is converting an underutilized vial line at Piombino Dese into cartridges to bridge near-term shortage, with larger Fishers (Indiana) and Latina (Italy) lines not commercial until late 2026/early 2027. SHL Medical opened a $220M South Carolina autoinjector plant in April 2025 targeting 1.5B units. The risk cuts both ways: West's most differentiated film is FluroTec, supplied via its 49%-owned Daikyo Seiko partner — a concentration the market rarely prices. A GLP-1 demand air-pocket would also hit the same lines hardest.
What forces the reprice
Three tapes. First, EU Annex 1 (the revised sterile-manufacturing rules) is pushing drugmakers toward ready-to-use, pre-sterilized components — a mix shift directly into West's and Datwyler's highest-margin HVP/RTU lines, which West cites as a conversion driver. Second, the capacity-milestone tape: groundbreakings are not output, and the gap between announced and operational lines (Fishers, Latina, SHL Switzerland) is exactly where the supply story tightens or loosens. Third, the BIOSECURE Act, signed into law Dec 18, 2025 via the FY2026 NDAA, restricts federal dealings with Chinese biotech firms like WuXi — a reshoring tailwind for US/EU manufacturing broadly, though it targets CDMO/API services, not stoppers directly, and phases in over roughly 2+ years.
Be honest about size and earliness
This is a real-revenue chokepoint today, not a narrative. West did $3.07B in 2025 and Stevanato €1.19B — these are profitable, cash-generative incumbents, not pre-revenue optionality. But two cautions. The GLP-1 lift is genuine yet cyclical: it is ~20% of Stevanato revenue and the swing factor in West's HVP growth, so a demand pause or destocking (West and peers were whipsawed by COVID-vial destocking in 2023–24) would compress the multiple fast. And the device/glass names beyond West carry disclosure and liquidity gaps: Ypsomed, Datwyler and Gerresheimer trade in the US only as thin OTC ADRs, and SHL Medical is private — exposure to the autoinjector layer is hard to get cleanly in US-listed form. The cleanest, most liquid expression of this choke remains West (NYSE) and Stevanato (NYSE); everything else is an OTC or private wrapper. This is structure and a catalyst calendar, not investment advice.
Who owns the choke
AptarGroup, Inc.
Aptar Pharma's injectables division (elastomeric components for vials and prefilled syringes) grew 18% in Q3 2025 and 24% in Q4 2025, driven by GLP-1 elastomeric components; year-to-date September 2025 GLP-1-related sales were up over 40%. Pharma is the segment but injectables sit inside a broader, more cyclical dispensing portfolio.
- Bull
- Aptar's injectables elastomerics grew 18% in Q3 and 24% in Q4 2025 on GLP-1 demand, with year-to-date GLP-1 sales up over 40%.
- Bear
- Pharma injectables sit inside a broader, more cyclical dispensing portfolio, so the GLP-1 elastomeric tailwind is diluted by slower-growing consumer dispensing exposure.
Datwyler Holding AG
FY2025 group revenue CHF 1,100.5M with 3.1% organic growth; Healthcare Solutions makes system-critical elastomer closures for injectable drug containers. Expanded an ISO Class 7 cleanroom for coated stoppers in India (April 2025) and introduced low-extractable Omniflex ready-to-use stoppers for mRNA/mAb drugs. The US OTC ADR (DATWY) is effectively non-trading, so the SIX Swiss line (DTG.SW, CHF) is the reference quote.
- Bull
- Datwyler's Healthcare Solutions makes system-critical elastomer closures, expanding coated-stopper cleanroom capacity in India and launching low-extractable Omniflex stoppers for mRNA and mAb drugs.
- Bear
- FY2025 organic growth was just 3.1%, and with the US OTC ADR effectively non-trading the only live quote is the Swiss line (CHF) — not reachable from most US brokerages.
Gerresheimer AG (ADR)
Primary packaging specialist (Gx Elite glass vials, RTF prefillable syringes, cartridges) with ~€2.4B 2024 revenue including the 2025 Bormioli Pharma acquisition; expanding RTF syringe capacity in Queretaro, Mexico for North America. Frankfurt-listed (GXI); US OTC ADR GRRMY. 2025 marked by a guidance cut and restructuring pressure.
- Bull
- Gerresheimer's Gx Elite vials, RTF prefillable syringes and cartridges, plus Queretaro RTF capacity expansion for North America, position it across multiple injectable-component chokepoints.
- Bear
- A 2025 guidance cut and restructuring pressure weigh on a speculative name accessible only via a US OTC ADR with limited liquidity.
SHL Medical AG
Privately held Swiss autoinjector specialist; opened a $220M, 360,000-sq-ft autoinjector manufacturing facility in North Charleston, South Carolina in April 2025 (300 jobs), and stated it remained on track to supply 1.5 billion autoinjector units globally in 2025 across sites in Taiwan, the US and Switzerland. Devices used heavily for GLP-1 therapies.
- Bull
- SHL Medical is a leading autoinjector specialist that opened a $220M South Carolina plant and targeted 1.5 billion units in 2025, riding the GLP-1 device demand wave.
- Bear
- It is privately held with no listed exposure vehicle, so the autoinjector growth story offers no direct tradable path for public investors.
Stevanato Group S.p.A.
Stevanato makes prefilled syringes (Nexa, its fastest-growing product), EZ-fill vials and cartridges for biologics and GLP-1 drugs. FY2025 revenue was EUR 1.186B (+7%, +9% constant currency), with GLP-1s ~19-20% of sales and GLP-1 revenue up >50% y/y; its Fishers, Indiana plant is being built as the North American high-value hub, reaching full productivity in 2028.
- Bull
- Stevanato's Nexa syringes, EZ-fill vials and cartridges sit across three chokepoints, with FY2025 revenue up 7% and GLP-1 revenue up >50% as its Fishers hub builds out.
- Bear
- The Fishers North American hub only reaches full productivity in 2028, so near-term margins absorb ramp costs ahead of the high-value capacity coming online.
West Pharmaceutical Services, Inc.
FY2025 net sales of $3.074B (+6.3%); high-value-product components (NovaPure, FluroTec, Westar coated stoppers/plungers) were 48% of net sales (Q4 2025/Q1 2026) and grew ~20.3% reported (~15% organic) in Q4 2025, driven by GLP-1 and Annex-1 ready-to-use conversion. Q1 2026 net sales jumped 21.1% to $844.9M with EPS of $2.13. Holds a 49% equity stake in FluroTec-maker Daikyo Seiko.
- Bull
- West is the textbook elastomer choke, with high-value NovaPure/FluroTec/Westar components 48% of sales growing ~20% in Q4 on GLP-1 and Annex-1 ready-to-use conversion.
- Bear
- Growth leans heavily on sustained GLP-1 volumes and Annex-1 conversion timing, so any slowdown in those demand drivers would pressure the high-value mix.
Ypsomed Holding AG
Swiss maker of autoinjectors and pen injectors (Ypsomed Delivery Systems segment) used for GLP-1, diabetes and biotech self-medication; primary listing SIX Swiss (YPSN). US-listed only as thin OTC line YPHDF (Pink Limited Info). The device that pairs with the cartridge/syringe at the patient-facing end of the choke.
- Bull
- Ypsomed's autoinjectors and pen injectors are the patient-facing device pairing with cartridges and syringes, leveraged to GLP-1, diabetes and biotech self-medication demand.
- Bear
- US access is only a thin Pink Limited Info OTC line, and a speculative device-tier name remains dependent on continued GLP-1 self-injection volume growth.
Catalyst calendar
- 2026-12-18BIOSECURE Act — OMB initial 'companies of concern' designation list due (within 12 months of Dec 18, 2025 enactment)highNaming Chinese biotech entities (e.g. WuXi) under the now-enacted BIOSECURE Act sharpens the reshoring tailwind for US/EU drug manufacturing and the qualified-component suppliers feeding it.
- 2026-07-23West Pharmaceutical Q2 2026 resultsmediumConfirms whether GLP-1 and Annex-1 ready-to-use conversion are still driving ~20% HVP component growth or whether destocking is returning to the elastomer-closure choke.
- 2026-08-06Stevanato Group Q2/H1 2026 resultsmediumTests the syringe/cartridge capacity-shortage narrative and progress of the Fishers and Latina RTU lines that determine when announced cartridge capacity becomes operational output.
- 2027-01-01Stevanato Fishers (Indiana) and Latina (Italy) RTU cartridge lines targeted commercial late 2026/early 2027mediumThe transition of these announced lines from construction to qualified output is the milestone that either relieves or extends the GLP-1 cartridge bottleneck at the heart of the choke.